The GreenLight Clinical team is established and run by a group of highly-regarded physicians and researchers with a multi-disciplinary skillset, and a proven track record in delivering high-quality research output to our clients.
Our staff of experienced, knowledgeable clinical trial professionals aims to provide the highest quality research outcomes for our partners, and as a full-service provider, our teams cover all aspects of clinical trial management, drug & device development, and global regulatory affairs.
Director, Chairman of the Board
Andrew Chang – MBBS(Hons), PhD (USyd), FRANZCO, FRACS
Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. Dr Chang holds an academic appointment of Clinical Associate Professor at the University of Sydney.
Dr Chang is Consultant Vitreoretinal Surgeon and the Head of the Retinal Unit at the Sydney Eye Hospital. He is the Medical Director of Sydney Retina Clinic.
He graduated from University of Sydney Medical School, underwent ophthalmology training at the Sydney Eye Hospital and fellowship training at Royal Victorian Eye and Ear Hospital and in the United States. He was awarded a PhD for research into retinal and choroidal angiography performed in the Universities of California and Sydney.
Dr Chang commitment to international ophthalmology includes Secretary General of the Asia-Pacific Vitreoretinal Society (APVRS). He is a clinician advisor to the Department of Health Australia. He is a Director of the RANZCO Board and the Sydney Eye Hospital Foundation Board. Professional awards include the Achievement Award and Distinguished Service Award of the Asia Pacific Academy of Ophthalmology (APAO) and the RANZCO Excellence in Teaching Award.
Dr Chang is enthusiastically involved in basic science and clinical trials research receiving research grant funding in Australia and USA. His research is extensively published in peer-reviewed scientific literature. He serves on the editorial boards of scientific peer-reviewed journals including Clinical and Experimental Ophthalmology.
In wider healthcare activities, Dr Chang is engaged in the complexities of modern hospital healthcare delivery. He supports new medical drug and devices by engaging in clinical trials development. He is driving strategies aimed at better patient engagement with healthcare professionals using the latest in cloud, IoT and Artificial Intelligence.
Interim CEO and Group General Counsel
Franz D’Lima has over 20 years of experience as a senior corporate lawyer and general counsel in global FMCG, healthcare, and B2B industries. His diverse experience in ANZ, EMEA, and APAC (including emerging markets such as China and India), has helped him develop an acute understanding of the legal environment in multiple jurisdictions as well as an appreciation of cross-cultural sensitivities.
Franz approaches legal issues from a commercial perspective and has acquired a reputation as a trusted business partner. He has managed a number of complex projects including the successful transition of a US$100M healthcare business in Japan, the divestment of multi-million dollar cigarette paper businesses in Indonesia, and the Philippines, and established manufacturing facilities and R&D centres across the Asia Pacific region.
Franz has successfully led and defended multifaceted legal actions against the government and quasi-government agencies most notably in China, Korea, the Philippines, and Thailand.
Franz is a qualified lawyer in both England & Wales, and New South Wales, Australia and specialises in M&A, divestments, strategic alliances, intellectual property, data privacy, anti-bribery, risk and compliance management.